ARB, ACEi, DRi Effects on COVID-19 Course Disease (BIRCOV)
Effects of RAS Inhibitors (ARB, ACEi, DRI) in People With Hypertension 1-2 Stages on the Course of COVID-19 (BIRCOV Trial: ARB, ACEI, DRi Effects on COVID-19)
Sponsor: Medical Practice Prof D. Ivanov
Listed as NCT04364984, this observational or N/A phase trial focuses on COVID-19 and Hypertension and remains completed. Sponsored by Medical Practice Prof D. Ivanov, it has been updated 8 times since 2020, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Apr 2023 — Jul 2024 [monthly]
Completed
-
Mar 2022 — Apr 2023 [monthly]
Completed
-
Sep 2021 — Mar 2022 [monthly]
Completed
Status: Recruiting → Completed
▶ Show 3 earlier versions
-
Apr 2021 — Sep 2021 [monthly]
Recruiting
-
Jan 2021 — Apr 2021 [monthly]
Recruiting
-
May 2020 — Jan 2021 [monthly]
Recruiting
First recorded
Apr 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medical Practice Prof D. Ivanov
For direct contact, visit the study record on ClinicalTrials.gov .